Contraception in Gynecologic Oncology: Pharmacologic Determinants, Thromboembolic Risk, and Tumor-Specific Clinical Selection
Contraceptive counseling in gynecologic oncology requires integration of medical eligibility, contraceptive pharmacology, tumor characteristics, and treatment status. This narrative review synthesizes professional guidance and selected clinical, epidemiologic, and mechanistic literature, distinguishing direct post-diagnosis contraceptive outcomes from indirect evidence. General-population studies associate combined oral contraception with increased venous thromboembolism (VTE), with differences between formulations; most progestin-only pills, implants, and levonorgestrel intrauterine systems show no consistent increase, whereas depot medroxyprogesterone acetate has a VTE signal. These estimates do not quantify formulation-specific risk in patients with gynecologic cancer. Histotype and endocrine treatment warrant particular attention in low-grade serous and endometrioid ovarian carcinomas, adult granulosa cell tumors, and low-grade endometrial stromal sarcoma. Molecular prognostic markers have not been validated as predictors of contraceptive effects on recurrence or survival. A qualitative framework, an annotated method-selection table, and a decision pathway organize formulation, host, tumor, treatment, and procedural considerations, including perimenopausal use and regional prescribing differences. The framework is an author-derived synthesis rather than a validated prediction model, evidence-grading system, or medical eligibility classification. It is intended to support individualized, multidisciplinary counseling alongside established recommendations. Prospective studies of post-diagnosis exposure, recurrence, survival, and vascular outcomes are needed before its clinical utility can be established.
Authors
- Dimitrios‐Efthymios Vlachos (ORCID: https://orcid.org/0000-0003-3740-2575)
- Nikolaos Thomakos (ORCID: https://orcid.org/0000-0003-0962-3549)
- Antonia Varthaliti (ORCID: https://orcid.org/0009-0008-8725-7103)
- Chrysi Christodoulaki (ORCID: https://orcid.org/0000-0002-2990-640X)
- Γεωργία Μπουντουράκη
- Vasilios Lygizos
- Dimitris Baroutis (ORCID: https://orcid.org/0009-0008-1546-1738)
- G. Daskalakis (ORCID: https://orcid.org/0000-0001-7108-211X)
- Periklis Panagopoulos (ORCID: https://orcid.org/0000-0001-6565-1558)
- Rafaela Panagopoulou
- Vasilios Pergialiotis (ORCID: https://orcid.org/0000-0003-4510-1633)
Institutions
- National and Kapodistrian University of Athens (GR)
- Alexandra Hospital (GR)
- Chania General Hospital ”St. George” (GR)
- University General Hospital Attikon (GR)
Publication Details
- Journal
- Cancers
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3390/cancers18223695
- Primary Topic
- Reproductive Health and Contraception
- Type
- article
- Field-Weighted Citation Impact
- 0.00